Adicet Bio logo
Adicet Bio
ACET | NASDAQ
Chart Builder DCF Calculator
$2.75
-$0.03 (-1.08%)
At close: Nov 16, 2026, 4:00 PM ET
$2.75
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Adicet Bio Company Profile

Company profile explained

Company Profile

Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.

Key Executives

Name Position
Chen Schor Chief Executive Officer, President & Director
Brian Nicholas Harvey Chief Financial Officer
Donald Healey Chief Technology Officer
Amy Locke Chief Human Resource Officer
Blake Aftab Senior Vice President & Chief Scientific Officer
Julie Maltzman Chief Medical Officer
Lloyd Klickstein Interim Chief Medical Officer & Director

Latest SEC Filings

Date Type Title
Oct 28, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 23, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Sep 28, 2026 8-K Current Report
Sep 08, 2026 8-K Current Report
Sep 01, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 07, 2026 4 Filing
Aug 05, 2026 10-Q Quarterly Report
Aug 05, 2026 8-K Current Report
Jun 23, 2026 4 Filing
View All SEC Filings ➞
Adicet Bio
Adicet Bio logo
Country United States
IPO Date Jan 26, 2018
Industry Biotechnology
Sector Healthcare
Employees 102
CEO Chen Schor

Contact Details

131 Dartmouth Street Boston, Massachusetts 02116 United States

Stock Details

Ticker Symbol ACET
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001720580
CUSIP Number 007002207
ISIN Number US0070022076
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.